SII inks agreement with Oxford to manufacture chimeric PB vaccine

Serum Institute of India Pvt. Ltd. has inked a groundbreaking licensing agreement with the University of Oxford to manufacture and distribute “a chimeric protein-based vaccine” targeting Meningitis-B, announced in a press release on Tuesday, April 16. The collaborative effort spanning five years aims to combat the infection that poses severe risks to the brain and spinal cord.

Adar Poonawalla, the CEO of Serum Institute, expressed his commitment to global health and emphasised the significance of accessible vaccines in the battle against diseases. “This collaboration exemplifies a shared dedication to global health and underscores the importance of accessible vaccines.”

“This partnership represents a monumental leap forward in our fight against meningitis, ensuring life-saving protection reaches those who need it most,” he added. The top vaccine maker seeks to growth by selling shots to globetrotters.

This move comes on the heels of Serum Institute’s MenFive vaccine receiving pre-qualification from the World Health Organisation in July 2023, solidifying the company’s position as a key player in combating meningitis outbreaks worldwide.

Simon Warner, the Head of Licensing & Ventures – Life Sciences at Oxford University Innovation, hailed the agreement as a testament to Oxford’s dedication to vaccine innovation. He highlighted the university’s investment in developing effective vaccines, stressing the importance of academic licensing and successful commercial partnerships in addressing global health challenges.

“The Men-B vaccine agreement with the Serum Institute of India is another example of vaccine innovation at the University of Oxford. Oxford’s commitment and investment to develop efficacious, deployable vaccines will protect millions of lives and academic licensing and successful commercial partnerships that help solve global health challenges.” CNBCTV18